Nigella sativa: A potential natural protective agent against cardiac dysfunction in patients with type 2 diabetes mellitus

Abdullah Bamosa, Huda Kaatabi, Ahmed Badar, Akram Al-Khadra, Abdulmohsen Al Elq, Bodour Abou-Hozaifa, Fatma Lebda, Sameeh Al-Almaie, Abdullah Bamosa, Huda Kaatabi, Ahmed Badar, Akram Al-Khadra, Abdulmohsen Al Elq, Bodour Abou-Hozaifa, Fatma Lebda, Sameeh Al-Almaie

Abstract

Objectives: To study the effect of Nigella sativa supplementation on cardiac functions in Type 2 diabetic patients treated with oral hypoglycemic agents.

Background: Diabetes mellitus is associated with a high risk of cardiovascular morbidity and mortality. A number of reported beneficial effects of N. sativa on cardiovascular function were the inspiration for this study.

Materials and methods: Sixty patients with uncontrolled diabetes (hemoglobin A1c [HbA1c] >7%) and with no known cardiovascular complications were recruited from the outpatient diabetes clinic. They were assigned, by convenience, to two groups; the control group received activated charcoal as placebo while the test group received 2 g/day of powdered N. sativa for 1-year. All patients continued with their standard oral hypoglycemic agents. Echocardiography was used to evaluate the diastolic function, systolic function, and left ventricular mass (LVM) before the intervention and after 6 and 12 months of the treatment.

Results: HbA1c decreased significantly in the N. sativa group but did not change in the control group. Echocardiographic assessment in the control group showed impairment in diastolic function after 12 months, but there were no significant changes in fractional shortening (FS) or ejection fraction (EF). Furthermore, left ventricular (LV) dimensions at diastole and systole, LVM, and LVM index were significantly increased. In N. sativa group, no significant changes were found in diastolic function or LVM. LV dimension at systole was decreased while FS and EF were significantly increased after 6 and 12 months.

Conclusion: N. sativa supplementation may protect the hearts of type 2 diabetic patients from diastolic dysfunction while improving LV systolic function.

Keywords: Diabetes mellitus; Nigella sativa; diastolic function; echocardiography; left ventricular mass; systolic function.

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. 5th ed. Brussels, Belgium: International Diabetes Federation; 2011. [Last accessed on 2014 Sep 11]. International Diabetes Federation. IDF Diabetes Atlas. Available from: .
    1. Alhyas L, McKay A, Majeed A. Prevalence of type 2 diabetes in the States of the co-operation council for the Arab States of the Gulf: A systematic review. PLoS One. 2012;7:e40948.
    1. Wang CC, Reusch JE. Diabetes and cardiovascular disease: Changing the focus from glycemic control to improving long-term survival. Am J Cardiol. 2012;110(9 Suppl):58B–68.
    1. Johansen OE, Birkeland KI. Preventing macrovascular disease in patients with type 2 diabetes mellitus. Am J Cardiovasc Drugs. 2003;3:283–97.
    1. Wannamethee SG, Shaper AG, Lennon L. Cardiovascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease. Heart. 2004;90:1398–403.
    1. Tarquini R, Lazzeri C, Pala L, Rotella CM, Gensini GF. The diabetic cardiomyopathy. Acta Diabetol. 2011;48:173–81.
    1. Mercer BN, Morais S, Cubbon RM, Kearney MT. Diabetes mellitus and the heart. Int J Clin Pract. 2012;66:640–7.
    1. Bamosa AO, Kaatabi H, Lebdaa FM, Elq AM, Al-Sultanb A. Effect of Nigella sativa seeds on the glycemic control of patients with type 2 diabetes mellitus. Indian J Physiol Pharmacol. 2010;54:344–54.
    1. Mohtashami R, Amini M, Huseini FH, Ghamarchehre M, Sadeghi Z, Hajjagaee R, et al. Blood glucose lowering effects of Nigella sativa L. seeds oil in healthy volunteers: A randomized, double-blind, placebo-controlled clinical trial. J Med Plants. 2011;10:90–4.
    1. Kocyigit Y, Atamer Y, Uysal E. The effect of dietary supplementation of Nigella sativa L. on serum lipid profile in rats. Saudi Med J. 2009;30:893–6.
    1. Kaleem M, Kirmani D, Asif M, Ahmed Q, Bano B. Biochemical effects of Nigella sativa L seeds in diabetic rats. Indian J Exp Biol. 2006;44:745–8.
    1. Zaoui A, Cherrah Y, Lacaille-Dubois MA, Settaf A, Amarouch H, Hassar M. Diuretic and hypotensive effects of Nigella sativa in the spontaneously hypertensive rat. Therapie. 2000;55:379–82.
    1. El-Bahai MN, Al-Hariri MT, Yar T, Bamosa AO. Cardiac inotropic and hypertrophic effects of Nigella sativa supplementation in rats. Int J Cardiol. 2009;131:e115–7.
    1. Yar T, El-Hariri M, El-Bahai MN, Bamosa AO. Effects of Nigella sativa supplementation for one month on cardiac reserve in rats. Indian J Physiol Pharmacol. 2008;52:141–8.
    1. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation. 1978;58:1072–83.
    1. Wallerson DC, Devereux RB. Reproducibility of echocardiographic left ventricular measurements. Hypertension. 1987;9:II6–18.
    1. Foppa M, Duncan BB, Rohde LE. Echocardiography-based left ventricular mass estimation. How should we define hypertrophy? Cardiovasc Ultrasound. 2005;3:17.
    1. Schabelman S, Schiller NB, Silverman NH, Ports TA. Left atrial volume estimation by two-dimensional echocardiography. Cathet Cardiovasc Diagn. 1981;7:165–78.
    1. Semeniuk LM, Kryski AJ, Severson DL. Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice. Am J Physiol Heart Circ Physiol. 2002;283:H976–82.
    1. Rajan SK, Gokhale SM. Cardiovascular function in patients with insulin-dependent diabetes mellitus: A study using noninvasive methods. Ann N Y Acad Sci. 2002;958:425–30.
    1. Galderisi M. Diastolic dysfunction and diabetic cardiomyopathy: Evaluation by Doppler echocardiography. J Am Coll Cardiol. 2006;48:1548–51.
    1. Shrestha NR, Sharma SK, Karki P, Shrestha NK, Acharya P. Echocardiographic evaluation of diastolic function in asymptomatic type 2 diabetes. JNMA J Nepal Med Assoc. 2009;48:20–3.
    1. Faden G, Faganello G, De Feo S, Berlinghieri N, Tarantini L, Di Lenarda A, et al. The increasing detection of asymptomatic left ventricular dysfunction in patients with type 2 diabetes mellitus without overt cardiac disease: Data from the SHORTWAVE study. Diabetes Res Clin Pract. 2013;101:309–16.
    1. Arnlöv J, Lind L, Zethelius B, Andrén B, Hales CN, Vessby B, et al. Several factors associated with the insulin resistance syndrome are predictors of left ventricular systolic dysfunction in a male population after 20 years of follow-up. Am Heart J. 2001;142:720–4.
    1. Cioffi G, Giorda CB, Chinali M, Lenarda AD, Faggiano P, Lucci D, et al. Analysis of midwall shortening reveals high prevalence of left ventricular myocardial dysfunction in patients with diabetes mellitus: The DYDA study. Diabetes Res Clin Pract. 2013;101:236–42.
    1. Boskabady MH, Shafei MN, Parsaee H. Effects of aqueous and macerated extracts from Nigella sativa on guinea pig isolated heart activity. Pharmazie. 2005;60:943–8.
    1. Lutale JJ, Thordarson H, Gulam-Abbas Z, Vetvik K, Gerdts E. Prevalence and covariates of electrocardiographic left ventricular hypertrophy in diabetic patients in Tanzania. Cardiovasc J Afr. 2008;19:8–14.
    1. Struthers AD, Morris AD. Screening for and treating left-ventricular abnormalities in diabetes mellitus: A new way of reducing cardiac deaths. Lancet. 2002;359:1430–2.
    1. Lee M, Gardin JM, Lynch JC, Smith VE, Tracy RP, Savage PJ, et al. Diabetes mellitus and echocardiographic left ventricular function in free-living elderly men and women: The Cardiovascular Health Study. Am Heart J. 1997;133:36–43.
    1. Galderisi M, Anderson KM, Wilson PW, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study) Am J Cardiol. 1991;68:85–9.
    1. Felicio JS, Ferreira SR, Plavnik FL, Moisés V, Kohlmann O, Jr, Ribeiro AB, et al. Effect of blood glucose on left ventricular mass in patients with hypertension and type 2 diabetes mellitus. Am J Hypertens. 2000;13:1149–54.
    1. Jarnert C, Landstedt-Hallin L, Malmberg K, Melcher A, Ohrvik J, Persson H, et al. A randomized trial of the impact of strict glycaemic control on myocardial diastolic function and perfusion reserve: A report from the DADD (Diabetes mellitus And Diastolic Dysfunction) study. Eur J Heart Fail. 2009;11:39–47.
    1. Langford MC. Type 2 diabetes and chronic systolic heart failure: Clinical implications. J Cardiovasc Nurs. 2004;19:S35–44.
    1. Vanninen E, Mustonen J, Vainio P, Länsimies E, Uusitupa M. Left ventricular function and dimensions in newly diagnosed non-insulin-dependent diabetes mellitus. Am J Cardiol. 1992;70:371–8.
    1. Lebda FM, Bamosa AO, Kaatabi H, Al-Elq A, Al-sultan A. Effect of Nigella sativa on hemodynamics, hemoglobin, and blood coagulation in patients with type 2 diabetes. Egypt J Haematol. 2012;37:73–80.
    1. Dehkordi FR, Kamkhah AF. Antihypertensive effect of Nigella sativa seed extract in patients with mild hypertension. Fundam Clin Pharmacol. 2008;22:447–52.
    1. Datau EA, Wardhana, Surachmanto EE, Pandelaki K, Langi JA, Fias Efficacy of Nigella sativa on serum free testosterone and metabolic disturbances in central obese male. Acta Med Indones. 2010;42:130–4.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever